![](https://investorshub.advfn.com/uicon/280555.png?cb=1594066301)
Monday, November 27, 2023 9:03:55 AM
Patented QuadraMune® Product Shown to Modulate Biochemical Pathway Associated with Major Depressive Syndrome
ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International, Inc. (TSOI), announced today a publication with Campbell Neurosciences and several academic institutions describing the importance of the indolamine 2,3 dioxygenase pathway in depression, as well as modulation of this pathway by QuadraMune®, a multi-patented nutraceutical that is commercially available.
The publication is freely available at PsyArXiv Preprints | Modulation of the Indolamine 2,3 Dioxygenase Pathway as a Means of Treating Depression (osf.io).
“QuadraMune® was developed as an immune stimulator for the prevention and treatment of COVID-19 and was granted several patents for this indication1,2. Subsequently, the science behind QuadraMune® was validated by numerous independent institutions3,4,” said Thomas Ichim, Ph.D., President, and Chief Executive Officer of Campbell Neurosciences and Board Member of Therapeutic Solutions International. “Through its ability to suppress activation of the indolamine 2,3 dioxygenase pathway, as well as preliminary data reported in our publication, we are eager to explore the utility of this approach in the area of major depressive disorder”.
Campbell Neurosciences is a subsidiary of Therapeutic Solutions International and has developed a blood-based test for suicidal propensity, as well as several therapeutic approaches to immunologically address mental health.
“Depression resistant to conventional medication is considered to be a “Silent Epidemic” and affects up to one of three patients5,” said Noelle Ramos, first author of the publication and consultant to the Company. “Through combining the cutting-edge immunological experiences of Dr. Ichim, as well as the deep neurology and medical knowledge of the other coauthors, I am confident that this paper is a first step in shifting our perception of depression from a strictly biochemical disorder to a more immunological associated condition.”
“QuadraMune® is one of several approaches using science-based nutraceuticals developed by the Company,” said Timothy Dixon, President and CEO of Therapeutic Solutions International. “While we are usually reporting on medical advancements accomplished by our regenerative medicine division, the fact that we have products commercialized is an interesting aspect of our company that I suspect will be receiving more attention as the state of our progress advances. The caliber of the current paper’s co authors we see as a positive signal”.
Recent TSOI News
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/31/2024 08:51:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 04:47:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 12:46:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 12:44:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/30/2024 06:46:26 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 04:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 10:03:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:15:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:12:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 11:16:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/08/2024 05:15:25 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 11:34:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 08:42:55 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/17/2024 11:15:01 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/04/2024 09:03:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 07:44:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 05:39:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:17:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 06:50:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 05:44:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:24:52 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 11:10:01 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM